GASTROINTESTINAL CANCER—COLORECTAL AND ANAL

A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY- CRC01.Read more...

Related Posts

DEVELOPMENTAL THERAPEUTICS—IMMUNOTHERAPY

 32

HEALTH SERVICES RESEARCH AND QUALITY IMPROVEMENT

 14

DEVELOPMENTAL THERAPEUTICS—MOLECULARLY TARGETED AGENTS ...

 49